-+ 0.00%
-+ 0.00%
-+ 0.00%

Vivani Medical Presents Phase 1 NPM-139 Data Showing No Treatment-Related Adverse Events

PUBT·11/12/2026 13:50:20
Vivani Medical Presents Phase 1 NPM-139 Data Showing No Treatment-Related Adverse Events
  • Vivani Medical completed its Phase 1 SLIM-1 trial of NPM-139, an investigational semaglutide implant targeting once- or twice-yearly dosing.
  • No treatment-related adverse events occurred among 10 implant recipients; five of 10 Wegovy recipients experienced treatment-related gastrointestinal adverse events.
  • Average weight loss reached 0.67 kg with NPM-139 versus 0.76 kg with Wegovy over four weeks.
  • Drug release showed no measurable initial burst, supporting further clinical development.
  • Novo Nordisk's evaluation of NPM-139 remains ongoing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.